small
noncod
rna
nucleotid
ribonucl
acid
emerg
import
transform
biolog
evolut
almost
three
decad
microrna
mirna
short
interf
rna
sirna
two
signific
categori
small
rna
exert
import
effect
bone
endocrinolog
skeletolog
therefor
clarifi
express
function
import
molecul
bone
endocrin
physiolog
patholog
great
signific
improv
potenti
therapeut
valu
metabolismassoci
bone
diseas
present
review
highlight
recent
advanc
made
understand
function
molecular
mechan
small
noncod
rna
bone
metabol
especi
potenti
therapeut
valu
bonerel
diseas
discoveri
small
noncod
rna
includ
microrna
mirna
short
interf
rna
sirna
hamilton
baulcomb
lee
et
al
reinhart
et
al
aravin
et
al
revolution
understand
regul
gene
express
effect
small
rna
gene
express
control
gener
inhibitori
correspond
regulatori
mechan
therefor
collect
subsum
head
rna
silenc
central
theme
throughout
small
noncod
rna
mainli
serv
specif
factor
combin
effector
protein
target
messeng
rna
mrna
complementari
base
pair
core
compon
effector
machineri
member
argonaut
protein
superfamili
compar
convent
small
therapeut
molecul
mirna
sirna
offer
advantag
highli
potent
abl
act
nondrugg
target
instanc
protein
lack
enzymat
function
conform
inaccess
tradit
drug
molecul
design
affect
virtual
gene
interest
daka
peer
regul
gene
genom
mediat
mirna
sirna
occur
level
chromosom
segreg
chromatin
structur
rna
process
rna
stabil
transcript
translat
carthew
sontheim
mirna
nucleotid
rna
regul
gene
express
target
mrna
posttranscript
level
purpos
express
product
genom
origin
organ
liu
paroo
ha
kim
mirna
gene
transcript
execut
rna
polymeras
ii
nucleu
lead
format
primari
mirna
primirna
doublestrand
stemloop
structur
primirna
cleav
microprocessor
complex
compris
drosha
microprocessor
complex
subunit
form
precursor
mirna
premirna
nt
subsequ
premirna
transport
exportin
nucleu
cytoplasm
sirna
deriv
transposon
transgen
trigger
viru
transcrib
cellular
gene
usual
consist
base
pair
regul
gene
express
via
highli
precis
mechan
sequencedirect
gene
silenc
transport
cytoplasm
premirna
long
doublestrand
rna
dsrna
process
dicer
known
special
ribonucleas
rnase
iiilik
enzym
form
mirna
sirna
respect
passeng
strand
sens
strand
guid
strand
antisens
strand
mirna
sirna
cleav
argonaut
compon
belong
rnainduc
silenc
complex
risc
subsequ
guid
strand
antisens
strand
mirna
sirna
remain
associ
risc
wherea
passeng
strand
detach
activ
risc
final
guid
strand
mirna
guid
activ
risc
target
mrna
partial
complementar
complementari
pair
mrna
matur
mirna
typic
occur
untransl
region
utr
former
seed
region
nucleotid
end
latter
mirna
bind
site
centr
site
supplementari
site
bulg
site
consid
atyp
contrast
sirna
must
fulli
complementari
target
mrna
meister
tuschl
hammond
et
al
differ
combin
mode
mirna
sirna
target
mrna
produc
differ
target
gene
silenc
effect
close
relat
common
event
dicer
process
risc
format
regul
mirna
sirna
degrad
occur
either
transcript
posttranscript
level
transcript
major
point
regul
mirna
biogenesi
alway
close
associ
activ
polymeras
ii
kim
et
al
drosha
process
confer
anoth
import
point
biogenesi
mirna
sirna
instanc
group
exoribonucleas
call
small
rnadegrad
nucleas
sdn
protein
report
affect
stabil
mirna
plant
ramachandran
chen
howev
nucleas
respons
mirna
degrad
anim
remain
unknown
two
promin
question
close
relat
degrad
mirna
sirna
specif
mark
destruct
ribonucleas
catalys
degrad
reaction
major
differ
mirna
sirna
former
multipl
mrna
target
wherea
latter
highli
specif
one
target
sinc
discoveri
sirna
dsrna
use
research
tool
studi
gene
function
variou
cell
type
howev
mammalian
cell
verifi
deliveri
long
dsrna
close
relat
activ
interferon
ifn
pathway
part
defenc
mechan
viral
infect
gantier
william
effect
either
sequencedepend
independ
special
care
taken
design
sirna
therapeut
mechan
pathway
mirna
sirna
gene
silenc
summar
fig
bone
remark
tissu
play
key
role
critic
function
human
physiolog
consist
fortif
movement
support
vital
organ
miner
storag
homeostasi
hous
multipl
progenitor
cell
hematopoiet
mesenchym
cell
mani
cell
subset
includ
osteoblast
osteoclast
adipocyt
involv
bone
develop
balanc
bone
format
remodel
reabsorpt
extrem
import
normal
bone
metabol
caplan
denni
gimbl
et
al
gimbl
et
al
osteoblast
boneform
cell
deriv
bone
marrow
stromal
cell
produc
dens
crosslink
collagen
special
protein
osteoclast
larg
multinucl
boneresorb
cell
aris
monocytemacrophag
lineag
secret
hydrogen
ion
dissolv
miner
compon
bone
matrix
lytic
enzym
cathepsin
k
digest
bone
matrix
mainli
type
collagen
osteocyt
starshap
cell
repres
termin
differenti
osteoblast
commonli
found
matur
bone
permeat
miner
bone
matrix
bone
remodel
continu
adulthood
resorpt
old
bone
osteoclast
subsequ
format
new
bone
osteoblast
martin
number
bonerel
diseas
bone
defect
osteoporosi
osteolysi
osteonecrosi
osteoarthr
bone
cancer
lead
seriou
burden
qualiti
life
worldwid
bone
destruct
begin
exceed
bone
format
age
year
old
lead
local
system
reduct
bone
mass
well
known
osteoporosi
individu
osteoporosi
bone
fractur
repres
lifethreaten
event
risk
fractur
doubl
everi
bone
lost
rodan
martin
bone
metastasi
occur
approxim
patient
advanc
prostat
breast
cancer
suva
et
al
bone
metastas
lead
excess
bone
loss
gener
classifi
osteolyt
bone
destruct
lead
bone
deposit
regard
osteoblast
bone
format
bone
degrad
deposit
verifi
occur
earli
metastat
process
alway
incur
tumour
metastas
bone
suva
et
al
increas
molecular
understand
diseasecaus
diseasepromot
gene
bone
patholog
led
discoveri
numer
new
molecular
target
prevent
treatment
variou
bonerel
disord
flourish
scientif
field
molecular
mechan
therapeut
applic
small
noncod
rna
mirna
sirna
involv
bonerel
diseas
wide
investig
numer
studi
howev
date
mirna
sirna
target
therapybas
clinic
trial
musculoskelet
disord
initi
current
review
focu
role
mirna
regul
bone
format
metabol
emphasi
potenti
therapeut
strategi
meidiat
mirna
sirna
treatment
bonerel
diseas
bone
mesenchym
stem
cell
bmsc
origin
bone
marrow
possess
multipl
differenti
potenti
differenti
osteoblast
adipocyt
chondrocyt
tencerova
kassem
osteoblast
major
cell
type
bone
develop
tissu
engin
noronhamato
et
al
multipl
transcript
factor
particip
osteogen
differenti
product
miner
extracellular
matrix
ecm
synthes
osteoblast
fine
regul
differ
mirna
among
downstream
molecul
osterix
pivot
osteoblastspecif
transcript
factor
activ
relev
gene
involv
differenti
preosteoblast
matur
osteoblast
osteocyt
molecular
mechan
two
bone
specif
factor
regul
osteoblastogenesi
extens
describ
previou
review
fang
et
al
mani
mirna
express
osteogen
process
induc
bmsc
includ
cell
prolifer
growth
matrix
matur
miner
new
bone
format
fig
sever
mirnaprofil
tool
high
throughput
sequenc
small
rna
librari
quantit
real
timepolymeras
chain
reaction
rtpcr
lock
nucleic
acid
primer
microarray
analysi
use
screen
osteogenesisassoci
mirna
hu
et
al
li
et
al
et
al
microarray
analysi
wide
use
investig
genomewid
mirna
express
provid
fluctuat
inform
variou
mirna
osteogen
differenti
mirna
array
profil
method
appli
identif
mirna
relat
osteogen
differenti
differ
cell
line
although
mani
mirna
confirm
either
descend
ascend
osteogen
differenti
li
et
al
et
al
inos
et
al
li
et
al
eskildsen
et
al
includ
fang
et
al
actual
concern
gene
express
relat
skelet
format
biolog
dynam
characterist
sever
vital
osteorel
mirna
discuss
previou
review
fang
et
al
clarifi
impact
express
profil
mirna
bone
metabol
laxman
et
al
perform
nextgener
sequenc
mirna
deriv
primari
human
osteoblast
hob
cell
treat
dexamethason
dex
parathyroid
hormon
pth
discov
sever
mirna
target
runtrel
transcript
factor
target
bcatenin
exhibit
substanti
differ
target
geneexpress
level
dex
pth
treatment
laxman
et
al
huang
colleagu
report
neg
regul
osteogen
differenti
hbmsc
repress
homeobox
huang
et
al
bone
morphogenet
protein
induc
gene
promot
osteogen
differenti
activ
target
gene
hassan
et
al
addit
also
observ
neg
regul
osteoblast
differenti
target
liao
et
al
vishal
et
al
display
enhanc
osteoblast
differenti
indirectli
stabil
protect
smadspecif
ubiquitin
protein
ligas
mediat
degrad
target
antagonist
osteoblast
function
vishal
et
al
intriguingli
mechan
stimul
confirm
trigger
osteoblast
differenti
via
sever
mechanosign
transduct
pathway
play
moment
role
bone
homeostasi
harada
rodan
zaidi
hsieh
turner
reijnder
et
al
zuo
et
al
report
mechanosensit
mirna
exhibit
neg
effect
cyclic
mechan
stretch
cm
induc
osteoblastogenesi
lead
decreas
bone
format
vitro
vivo
zuo
et
al
innov
research
provid
us
feasibl
anabol
strategi
treatment
skelet
disord
result
patholog
mechan
load
therapeut
inhibit
well
known
skeleton
notabl
affect
reduc
differenti
capac
stem
cell
age
liu
rando
weilner
colleagu
report
first
time
microrna
content
microvesicl
senesc
cell
contribut
age
system
environ
compromis
osteoblastogenesi
weilner
et
al
indic
endotheli
secret
within
senesc
cellderiv
microvesicl
taken
mesenchym
stem
cell
suppress
osteogen
differenti
knock
addit
preclin
success
test
critic
size
defect
model
deng
et
al
deng
et
al
make
excit
target
bone
tissu
therapeut
near
futur
taken
togeth
differ
mirna
involv
bone
format
exhibit
divers
dynam
pattern
could
provid
us
abund
inform
regul
osteogenesi
howev
variou
vitro
observ
remain
investig
preclin
vivo
potenti
promis
candid
screen
delib
explor
prove
mirna
target
mrna
complementari
base
pair
differ
site
fig
schemat
gene
silenc
mechan
mirna
sirna
mirna
gene
transcript
execut
rna
polymeras
ii
nucleu
lead
format
primirna
cleav
drosha
form
premirna
subsequ
premirna
transport
exportin
nucleu
cytoplasm
sirna
exogen
product
origin
deriv
directli
transposon
transgen
trigger
viru
transport
cytoplasm
premirna
long
dsrna
process
dicer
form
mirna
sirna
separ
sens
strand
mirna
sirna
cleav
compon
risc
remain
antisens
strand
mirna
sirna
guid
activ
risc
target
mrna
partial
complementar
complementar
respect
lead
differ
target
gene
silenc
effect
argonaut
risc
rnainduc
silenc
complex
region
exert
biolog
function
translat
repress
andor
follow
deadenyl
degrad
mrna
target
bazzini
et
al
djuranov
et
al
multipl
signal
pathway
verifi
particip
skelet
develop
bone
format
good
understand
divers
signal
great
import
manipul
osteoblastogenesi
mediat
mirna
number
signal
pathway
prove
govern
osteoblastogen
differenti
bmsc
includ
bmptgfb
wnt
transduct
mapk
signal
notch
signal
igf
signal
rankopgrankl
signal
etc
fang
et
al
zhao
et
al
recent
li
et
al
indic
could
imped
osteogen
differenti
hbmsc
target
lowdens
lipoproteinreceptorrel
protein
via
inactiv
wntbcatenin
signal
li
et
al
singlepass
transmembran
protein
absenc
variat
shown
result
decreas
bone
mass
osteoporosi
cui
et
al
saarinen
et
al
xiao
group
demonstr
play
posit
role
osteoblast
differenti
reduc
signal
transduc
activ
transcript
level
lead
dramat
increas
express
xiao
et
al
origin
regard
signal
molecul
particip
immun
regul
via
interferon
pathway
meraz
et
al
sever
studi
also
indic
serv
import
neg
regul
osteogen
differenti
suppress
express
osterix
vitro
vivo
kim
et
al
tajima
et
al
variou
molecul
relat
osteoclast
commit
rankl
mcsf
lead
chang
osteoclast
activ
vitro
well
alter
bone
resorpt
vivo
activ
transcript
factor
homeobox
lipoproteinreceptorrel
protein
mcsf
macrophag
colonystimul
factor
runtrel
transcript
factor
opg
osteopontegrin
pten
phosphatas
tensin
homologu
rankl
receptor
activ
nfkb
ligand
signal
transduc
activ
transcript
special
atrich
sequencebind
protein
apart
target
also
neg
affect
osteoblast
differenti
target
special
atrich
sequencebind
protein
via
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
mapk
pathway
addit
wei
colleagu
indic
inhibit
osteoblast
prolifer
decreas
cyclin
accumul
simultan
suppress
osteoblast
differenti
decreas
accumul
embryogenesi
postnat
howev
studi
could
confirm
whether
put
target
notch
gene
might
addit
account
capabl
two
mirna
modul
osteoblastogenesi
around
time
bae
et
al
verifi
target
multipl
compon
notch
signal
pathway
includ
jag
regul
osteoblastogenesi
bone
homeostasi
bae
et
al
consid
signific
role
notch
signal
pathway
abnorm
osteoblastogenesi
osteosarcoma
engin
et
al
investig
function
interact
famili
notch
signal
could
potenti
lead
effici
therapeut
bone
cancer
equilibrium
bone
format
osteoblast
bone
resorpt
osteoclast
subject
fine
tight
regul
normal
bone
metabol
karsenti
wagner
tanaka
et
al
disrupt
balanc
decreas
bone
format
andor
excess
bone
resorpt
lead
develop
osteoporosi
zaidi
rachner
et
al
crosstalk
osteoblast
osteoclast
critic
maintain
equilibrium
govern
osteoblastdirect
osteoclast
bone
resorpt
osteoclastdirect
osteoblast
bone
format
zaidi
martin
sim
monocytemacrophag
deriv
cell
type
osteoclast
mainli
locat
near
bone
format
surfac
tanaka
et
al
vaananen
surviv
prolifer
function
differenti
osteoclast
modul
variou
cytokin
exogen
hormon
del
fattor
et
al
confirm
receptor
activ
nfkb
ligand
rankl
macrophag
colonystimul
mcsf
produc
activ
cell
osteoclast
two
key
cytokin
involv
osteoclastogenesi
karsenti
wagner
tanaka
et
al
del
fattor
et
al
furthermor
immunoreceptor
tyrosinebas
activ
motif
itam
depend
costimulatori
signal
also
essenti
osteoclastogenesi
koga
et
al
mani
transcript
factor
especi
cfo
nfkb
fundament
normal
differenti
monocyt
precursor
osteoclast
griqoriadi
et
al
iotsova
et
al
franzoso
et
al
mirna
also
control
osteoclastogenesi
target
relev
gene
express
involv
delic
process
fig
studi
express
pattern
mirna
reveal
mirna
highli
express
matur
osteoclast
precursor
kagiya
nakamura
function
famili
systemat
summar
excel
review
tang
et
al
well
document
osteoblasttoosteoclast
commun
occur
via
direct
cellcel
contact
iri
et
al
negishikoga
et
al
understand
whether
effect
paracrin
pathway
exist
interact
two
cell
type
li
colleagu
conduct
mirnamedi
osteoclastdirect
osteoblast
bone
format
ovariectom
ovx
mice
indic
inhibit
osteoclastderiv
exosom
induc
significantli
suppress
osteoclastogenesi
li
et
al
addit
also
neg
control
osteogen
differenti
target
osterix
activ
transcript
factor
shi
et
al
wang
et
al
promot
osteoclastogenesi
via
pathway
target
phosphatas
tensin
homologu
pten
zhao
et
al
base
research
mirnamodul
osteoblastogenesi
osteoclastogenesi
mirnatarget
therapeut
metabol
bone
disord
osteoporosi
osteopenia
rheumatoid
arthriti
ra
relat
bone
destruct
anticip
approach
clinic
applic
mirnarel
bone
disord
potenti
target
therapeut
osteoporosi
result
imbal
osteoclast
bone
resorpt
osteoblast
bone
format
character
tissu
structur
deterior
low
bone
miner
densiti
teitelbaum
report
approxim
million
peopl
suffer
osteoporosi
osteoporot
fractur
common
complic
lead
high
healthcar
expenditur
loss
product
muruganandan
et
al
seelig
et
al
glucocorticoid
gc
immunosuppress
antiinflammatori
drug
extens
use
treat
inflamm
autoimmun
disord
infect
tait
et
al
howev
prolong
use
gc
close
associ
osteoporosi
gcinduc
osteoporosi
gcop
second
common
aetiolog
type
osteoporosi
kondo
et
al
weinstein
et
al
suppress
osteoblast
activ
differenti
matur
lifespan
regard
major
mechan
involv
gcinduc
inhibit
bone
format
weinstein
sato
et
al
moreov
capaci
marrow
adipogenesi
observ
glucocorticoidmedi
bone
deterior
well
tamura
et
al
common
degen
bone
diseas
elderli
women
postmenopaus
osteoporosi
caus
remodel
imbal
bone
format
bone
resorpt
due
oestrogen
defici
holroyd
et
al
sambrook
cooper
shi
colleagu
discov
suppress
gcinduc
osteoclast
differenti
target
rankl
osteoblast
cell
shi
et
al
first
report
regard
micrornatarget
rankl
osteoclastogenesi
howev
explor
dexamethason
dex
regul
express
osteoblast
remain
investig
wang
et
al
observ
protect
rat
gcinduc
bone
loss
fragil
regul
wnt
inhibitor
make
potenti
candid
allevi
gcop
wang
et
al
inhibit
histon
deacetylas
hdac
restor
acetyl
state
bcatenin
amelior
harm
effect
glucocorticoid
osteoblast
miner
ko
et
al
howev
long
term
effect
exogen
signal
immun
respons
tissu
integr
anim
physiolog
warrant
evalu
variou
investig
role
microrna
vivo
human
circul
monocyt
etiolog
osteoporosi
extens
establish
order
figur
potenti
biomark
target
therapeut
wang
et
al
illustr
neg
regul
three
potenti
osteoclastrel
gene
chemokin
cxc
motif
ligand
chemokin
cxc
motif
receptor
solut
carrier
famili
indic
circul
monocyt
might
serv
potenti
biomark
postmenopaus
osteoporosi
wang
et
al
addit
could
downregul
certain
gene
express
level
relat
osteoclastogenesi
inhibit
includ
cluster
differenti
phosphoprotein
associ
glycosphingolipid
microdomain
insulinlik
growth
factor
transduc
make
anoth
possibl
biomark
underli
postmenopaus
osteoporosi
cao
et
al
furthermor
identifi
potenti
biomark
postmenopaus
osteoporosi
accord
meng
et
al
microarray
analysi
meanwhil
et
al
observ
myocyt
enhanc
factor
markedli
decreas
osteoporot
patient
microarray
analysi
necessari
shift
bmsc
osteogen
adipogen
differenti
develop
osteoporosi
et
al
overexpress
shown
induc
postmenopaus
osteoporosi
imped
osteogen
differenti
hmsc
downregul
posit
correl
osterix
lv
et
al
weilner
colleagu
perform
explor
analysi
numer
mirna
serum
sampl
obtain
patient
recent
osteoporot
fractur
discov
significantli
upregul
wherea
downregul
also
demonstr
regulatori
effect
osteogen
differenti
bmsc
vitro
weilner
et
al
moreov
team
also
investig
express
level
circul
mirna
patient
diabet
bone
diseas
postmenopaus
osteoporosi
identifi
promis
circul
mirna
diabet
bone
diseas
promis
circul
mirna
postmenopaus
osteoporosi
heilmeier
et
al
identifi
evalu
patient
rel
high
risk
osteoporosisassoci
fragil
fractur
great
signific
diseas
prevent
manag
indepth
explor
differenti
express
mirna
bone
tissu
larger
valid
cohort
well
establish
confirm
whether
mirna
serv
potenti
pharmaceut
biomark
clinic
applic
therapeut
target
osteoporosi
downregul
cell
cycl
factor
cyclin
led
impair
bmsc
osteogen
differenti
aggrav
osteoporosi
dexamethasoneinduc
rodent
model
notch
signal
pathway
therefor
might
conceiv
therapeut
target
gcop
kang
et
al
li
et
al
report
imped
spong
via
construct
creloxpbas
hybrid
baculoviru
vector
demonstr
improv
bone
format
mitig
excess
bone
resorpt
osteoporot
bone
defect
rat
model
thu
pave
new
avenu
treatment
osteoporot
bone
defect
combin
osteogen
factor
function
mirna
li
et
al
addit
krzeszinski
colleagu
found
knockout
heterozyg
mice
exhibit
elev
bone
resorpt
reduc
bone
mass
target
transform
growth
factorbinduc
factor
indic
critic
osteoclast
suppressor
potenti
therapeut
strategi
combat
osteoporosi
could
exert
anticatabol
anabol
effect
compar
current
drug
sole
anticatabol
krzeszinski
et
al
innov
studi
pave
way
futur
epidemiolog
clinic
studi
investig
patholog
therapeut
role
pathway
human
well
establish
oxid
stress
play
critic
role
develop
postmenopaus
osteoporosi
attribut
larg
declin
enzymat
antioxid
system
manolaga
liao
et
al
illustr
express
significantli
enhanc
ovariectom
ovx
mice
tnfa
activ
nfkb
pathway
lead
suppress
forkhead
box
protein
essenti
defend
oxid
damag
caus
oestrogen
defici
osteoporosi
liao
et
al
studi
indic
nfkb
pathway
major
target
treatment
osteoporosi
howev
global
inhibit
nfkb
pathway
may
ideal
strategi
clinic
nfkb
signal
great
import
immnu
system
physiolog
thu
modul
downstream
signal
promis
strategi
addit
group
also
report
could
mediat
shift
bmsc
cell
lineag
adipocyt
osteoporosi
target
respect
liao
et
al
furthermor
tnfa
report
imped
bone
format
downregul
express
oestrogen
deficiencyinduc
osteoporosi
enhanc
express
yang
et
al
neg
regul
fgf
erkmapk
signal
pathway
aetiolog
bone
defect
mainli
includ
osteoporosi
trauma
bone
tumour
resect
minor
bone
defect
selfrehabilit
howev
bone
restor
difficult
case
critic
size
bone
defect
tradit
graft
includ
autograft
allograft
xenograft
introduct
metal
implant
gold
standard
treatment
defect
nevertheless
sever
common
complic
tissu
function
loss
implantrel
infect
implant
reject
restrict
therapeut
effect
method
recent
bone
tissu
engin
provid
rel
diseasefre
implant
damag
bone
without
impos
obviou
advers
effect
skeleton
environ
emerg
altern
strategi
resolv
problem
origin
tradit
therapi
bone
defect
bioactiv
biograd
scaffold
similar
microarchitectur
bone
tissu
fabric
variou
method
electrospin
meka
et
al
freez
dri
chola
et
al
lowtemperatur
rapid
prototyp
qin
et
al
print
zhao
et
al
etc
wide
use
acceler
enhanc
bone
repair
critic
size
bone
defect
biomaterialmedi
mirna
deliveri
bone
regener
extens
exploit
base
molecular
mechan
discuss
mirna
express
profil
bmsc
defect
site
differenti
alter
osteoinduct
osteoconduct
biomateri
thu
genet
modifi
scaffold
incorpor
variou
mirna
could
pave
way
new
manipul
osteoblastogenesi
osteoclastogenesi
bone
restor
palmieri
et
al
first
effort
investig
regul
mirna
osteoblastlik
cell
via
calcium
sulphat
ca
use
microarray
techniqu
provid
better
understand
molecular
mechan
interact
biomateri
bone
regener
palmieri
et
al
nanostructur
interfac
biomateri
shown
promot
bone
miner
regul
relev
mirna
express
mahmood
et
al
observ
mani
osteogen
gene
differenti
regul
silver
nanoparticl
agnp
mahmood
et
al
apart
investig
effect
differ
biomateri
whole
mirna
profil
numer
mirnatarget
strategi
vari
biomateri
treat
bone
defect
thoroughli
studi
antimirna
oligonucleotid
amo
complementari
target
mirna
use
suppress
express
certain
critic
mirna
osteoblast
differenti
yan
et
al
report
bmsc
sheet
incorpor
nonvir
oligonucleotid
vitamin
cinduc
method
display
significantli
improv
bone
regener
vivo
activ
pathway
via
target
yan
et
al
verifi
famili
could
neg
regul
extracellular
matrix
ecm
product
earli
stage
osteogenesi
kapina
et
al
inhibit
famili
could
promot
ecm
synthesi
osteoblastogenesi
jame
et
al
determin
inhibitorload
gelatin
nanofibr
scaffold
prepar
electrospin
could
increas
ecm
deposit
might
serv
novel
platform
exploit
mirnabas
therapeut
bone
defect
jame
et
al
identifi
serv
direct
neg
regul
master
transcript
factor
osteogenesi
fang
et
al
colleagu
fabric
porou
collagennanohydroxyapatit
scaffold
complex
demonstr
significantli
promot
osteogen
differenti
vitro
thu
offer
potenti
applic
bone
repair
tissu
engin
et
al
howev
complet
inhibit
function
mirna
may
trigger
unwant
sideeffect
thu
systemat
investig
stabil
deliveri
system
vivo
valid
remain
perform
verifi
therapeut
efficaci
antagomirnasbas
osteoconduct
scaffold
bone
engin
addit
osteogenesi
bmsc
sheet
greatli
amelior
chitosanhyaluron
acid
nanoparticl
therefor
mirnabas
cell
sheet
engin
might
serv
novel
approach
rapid
robust
bone
regener
clinic
deng
colleagu
report
poli
glycerol
sebac
pg
scaffold
load
bmsc
show
better
biocompat
bone
regener
repair
criticals
calvari
defect
csd
rat
deng
et
al
also
systemat
evalu
role
adipos
tissueorigin
stem
cell
asc
vitro
vivo
indic
knockdown
lentiviru
antisens
asc
exhibit
dramat
improv
repair
csd
target
deng
et
al
silver
nanoparticl
snp
compound
conjug
posit
regul
osteogenesi
schoolmeest
et
al
enhanc
osteogen
differenti
improv
alp
activ
calcium
miner
qureshi
et
al
thu
studi
provid
possibl
scaffold
combin
conjug
light
activ
mirna
deliveri
vehicl
capabl
modul
osteogen
differenti
use
light
noninvas
trigger
modal
moreov
incorpor
asc
porou
hydroxyapatit
scaffold
also
show
satisfactori
bone
repair
rat
tibial
defect
model
osseointegr
titanium
implant
surround
bone
tissu
great
import
immobil
larg
bone
defect
improv
load
capabl
titaniumbas
implant
microarcoxid
method
introduc
form
micropor
structur
instanc
chitosanhyaluron
acid
nanoparticl
coat
surfac
titanium
use
crosslink
method
could
promot
osteogen
differenti
hbmsc
wang
et
al
provid
uniqu
crosslinkingmedi
therapeut
approach
prepar
mirnaload
metal
implant
surfac
bone
repair
mirna
express
first
link
cancer
initi
chronic
lymphocyt
leukaemia
differ
type
malign
mirnezami
et
al
gener
recogn
mirna
function
tumourinhibitor
gene
wherea
other
altern
behav
oncogen
nugent
develop
cancer
attribut
dysregul
mirna
express
certain
extent
make
mirnatarget
intervent
promis
approach
diagnosi
well
treatment
differ
malign
primari
bone
tumour
encompass
broad
rang
type
includ
osteosarcoma
os
ewe
sarcoma
es
chondrosarcoma
cs
multipl
osteochondromatosi
moc
giant
cell
tumour
bone
gctb
etc
among
osteosarcoma
ewe
sarcoma
two
common
malign
primari
tumour
bone
nugent
santulli
role
target
gene
mirna
primari
bone
tumour
metastat
bone
tumour
elucid
elabor
review
nugent
current
appear
new
mirna
concomit
target
associ
bone
neoplasm
sun
colleagu
observ
suppressor
os
cell
metastasi
downregul
fibroblast
growth
factor
shi
et
al
found
prolifer
migrat
invas
epithelialmesenchym
transit
emt
os
cell
effect
prevent
overexpress
directli
target
sirtuin
sirt
shi
et
al
sirt
type
class
iii
histon
deacetylas
promot
tumourigenesi
metastasi
lin
et
al
moreov
sirt
also
direct
target
suppress
prolifer
os
cell
downregul
sirt
express
xu
et
al
wu
et
al
report
express
os
tissu
significantli
lower
adjac
nontumour
tissu
inhibit
os
cell
migrat
invas
target
encod
serv
tumoursuppress
oncogen
factor
depend
cancer
type
studi
first
time
discov
uniqu
function
osteosarcoma
progress
studi
explor
interconnect
pathway
relev
model
benefici
fulli
elucid
function
osteosarcoma
develop
zhou
et
al
observ
exert
oncogen
effect
os
cell
via
direct
inhibit
earli
growth
respons
neg
regul
cell
prolifer
cell
cycl
unoki
nakamura
indic
may
serv
promis
prognost
therapeut
target
os
colleagu
discov
upregul
could
inhibit
os
prolifer
migrat
invas
target
highmobl
group
athook
critic
chromosom
aberr
tumourigenesi
fusco
fedel
surviv
report
approxim
osteosarcoma
patient
lung
metastasi
siegel
pressey
rel
poor
surviv
might
caus
difficulti
elimin
cancer
stem
cell
csc
small
subset
tumour
cell
also
possibl
primari
caus
tumour
metastasi
relaps
mitra
et
al
shown
play
posit
role
osteoblastogenesi
could
suppress
csc
phenotyp
tumour
growth
os
inhibit
pathway
play
pivot
role
maintain
csc
function
lu
et
al
thu
metastasi
os
might
effect
prevent
use
certain
mirna
suppress
csc
function
reprogram
metabol
pathway
increas
de
novo
lipid
synthesi
repres
one
critic
common
featur
cancer
cell
precursor
de
novo
lipogenesi
atp
citrat
lyas
acli
crosslink
mevalon
pathway
fatti
acid
synthesi
one
signific
compon
acli
metabol
posttranscript
regul
zaidi
et
al
tumour
growth
metastasi
os
could
inhibit
target
acli
yield
effect
therapeut
approach
differ
cancer
xin
et
al
apart
inhibit
pathway
also
act
tumour
inhibitor
os
via
direct
suppress
friend
leukaemia
viru
integr
enhanc
oncogenesi
wu
et
al
first
observ
interact
os
cell
direct
interact
mirna
prolifer
os
cell
remain
investig
extens
bone
resorpt
one
featur
characterist
gtcb
caus
region
pain
high
risk
patholog
fractur
cowan
singh
rankexpress
monocyt
cell
regard
neoplast
compon
gtcb
atkin
et
al
thu
rankltarget
intervent
mirna
could
meaning
method
restrain
develop
gtcb
member
cluster
verifi
novel
inhibitor
osteoclastogenesi
osteolysi
target
rankl
cytokin
twist
gtcb
wang
et
al
also
restrain
osteoclast
differenti
bone
resorpt
gtcb
inhibit
matrix
parathyroid
hormonerel
protein
pthrp
wu
et
al
zhou
et
al
meanwhil
osteoclast
differenti
bone
resorpt
gctb
involv
variou
factor
therefor
might
influenc
factor
express
process
via
either
direct
indirect
way
requir
studi
near
futur
hypoxiainduc
factor
vascular
endotheli
growth
factor
vegf
hypoxiainduc
factor
overexpress
sacral
gctb
sampl
close
relat
tumour
microvessel
densiti
fu
et
al
guo
et
al
elucid
first
time
upregul
gctb
stromal
cell
suggest
effect
strategi
suppress
hypox
adapt
gctb
common
metastat
bone
tumour
carcinoma
deriv
prostat
breast
lung
et
al
first
propos
involv
mirna
metastasi
indic
initi
invas
metastasi
breast
cancer
et
al
signific
studi
open
door
investig
role
mirna
mediat
cancer
metastasi
bone
metastasi
one
typic
characterist
prostat
cancer
pc
clinic
usual
treat
androgen
depriv
therapi
reliev
symptom
restrain
tumour
growth
comprehend
molecular
mechan
mirna
regul
metastasi
essenti
improv
therapeut
outcom
patient
shah
et
al
liu
et
al
report
low
level
androgenregul
could
promot
pc
bone
metastasi
activ
src
erk
signal
pathway
suggest
src
activ
might
regard
potenti
biomark
patient
receiv
androgen
depriv
treatment
aberr
activ
ra
wnt
signal
critic
event
develop
pc
bone
metastasi
carter
et
al
kypta
waxman
report
restrain
bone
metastasi
rasactiv
pc
via
wnt
signal
pathway
target
transcript
factor
play
vital
role
enhanc
oncogen
activ
wnt
signal
pathway
upregul
depend
suppress
well
establish
transform
growth
factorb
tgfb
signal
promot
malign
tumourigen
tumour
cell
imped
tumour
growth
benignnorm
tissu
ao
et
al
tgfb
serv
moment
factor
facilit
bone
metastasi
activ
mammalian
target
rapamycin
mtor
function
observ
upregul
tgfb
smaddepend
transcript
progress
pc
bone
metastasi
translat
protein
neg
regul
mtor
kinas
identifi
downstream
target
pathway
siu
et
al
endotheli
nitric
oxid
synthas
eno
detect
clinic
pc
tissu
posit
correl
invas
metastasi
antiandrogen
resist
pc
nanni
et
al
yu
et
al
fu
colleagu
found
restrain
bone
metastasi
pc
target
eno
indic
two
mirna
might
use
clinic
predict
bone
metastasi
pc
patient
fu
et
al
even
though
regulatori
role
mirna
control
metastat
bone
tumor
well
describ
numer
investig
specif
network
interact
remain
explor
futur
osteoarthr
oa
preval
degen
bone
joint
diseas
character
progress
deterior
articular
cartilag
sclerosi
subchondr
bone
synovi
hyperplasia
martelpelleti
past
decad
increas
concern
function
therapeut
role
mirna
oa
eleg
review
systemat
elucid
mirnamedi
homeostasi
pathogenesi
oa
miyaki
asahara
wu
et
al
sondag
haggi
focu
sever
recent
report
mirna
involv
pathogenesi
target
therapeut
oa
hu
et
al
report
promot
inhibit
chondrocyt
prolifer
migrat
human
chondrocyt
cell
suppress
insulinlik
growth
factor
receptor
eukaryot
translat
initi
factor
gamma
play
pivot
role
facilit
translat
initi
prolifer
cancer
cell
coldwel
et
al
maloney
et
al
kang
et
al
observ
express
significantli
higher
oa
cartilag
normal
tissu
decreas
chondrocyt
ecm
synthesi
target
regul
tgfb
homeostasi
restor
cartilag
kang
et
al
addit
also
target
might
contribut
deterior
oa
proinflammatori
cytokin
inhibitor
chondrocyt
prolifer
collagen
biosynthesi
goldr
et
al
overexpress
induc
nitric
oxid
synthas
ino
strongli
contribut
cartilag
deterior
inflamm
abramson
et
al
rashe
colleagu
indic
upregul
human
oa
chondrocyt
could
effect
restrain
express
ino
via
activ
nfkb
pathway
rashe
et
al
addit
inhibit
express
recruit
activ
protein
overexpress
disintegrinlik
metalloproteinas
lead
aggrav
degrad
cartilag
matrix
oa
ji
et
al
similarli
could
suppress
inflamm
chondrocyt
apoptosi
oa
via
nfkb
pathway
target
death
receptor
respect
wang
et
al
zhang
et
al
inhibit
product
proteoglycan
imbal
collagen
ii
induc
fibroblast
growth
factor
among
import
pathogen
factor
oa
ellman
et
al
adamt
express
inhibit
transcript
target
thu
acceler
progress
oa
ji
et
al
addit
inflammatori
factormedi
cartilag
deterior
mechan
stress
also
signific
biochem
factor
involv
initi
progress
oa
especi
traumat
oa
yang
et
al
report
mechan
respons
significantli
increas
cyclic
load
stimul
target
histon
deacetylas
act
potent
suppressor
chondrocyt
hypertrophi
thu
inhibit
might
effect
therapi
prevent
treatment
traumat
oa
short
inflammationmedi
degener
apoptosi
cartilag
import
caus
progress
oa
regul
mirna
involv
pathophysiolog
process
oa
could
pave
new
anticip
therapeut
avenu
treat
degen
inflammatori
disord
silenc
gene
express
sequencespecif
manner
posttranscript
level
achiev
smallinterf
rna
sirna
initi
propos
fire
colleagu
develop
rapidli
treat
musculoskelet
disord
last
two
decad
fire
et
al
discoveri
process
open
door
develop
sirnabas
therapeut
recent
sirna
fulli
exploit
regul
express
variou
protein
involv
mani
therapeut
condit
osteoporosi
osteoarthr
bone
regener
etc
howev
sirnabas
therapi
still
gain
ground
musculoskelet
tissu
repair
bone
regener
tumour
suppress
advanc
understand
target
biolog
pathway
involv
bone
regener
also
rapid
progress
sirna
technolog
applic
sirna
bonerel
disord
great
therapeut
potenti
sirna
therapeut
target
osteoclastmedi
bone
resorpt
involv
osteoporosi
osteoarthr
well
elucid
excel
review
shi
et
al
grainger
review
mainli
focu
sirnamedi
bone
regener
sever
newli
releas
investig
treatment
bone
resorpt
use
sirnatarget
technolog
two
major
categori
ddss
use
sirna
deliveri
therapeut
applic
bone
regener
lipidbas
polymerbas
system
current
major
commerci
transfect
reagent
modifi
cation
liposomebas
system
farnesyl
pyrophosph
synthas
fpp
enzym
mevalon
pathway
inhibit
target
alendron
potent
fdaapprov
nitrogencontain
bisphosphon
drug
knockdown
fpp
activ
mediat
sirna
exhibit
select
inhibit
osteoclastmedi
bone
resorpt
promot
bone
mass
mainten
without
neg
effect
prolifer
preosteoblast
wang
et
al
first
report
knock
molecular
target
clinic
common
nitrogencontain
bisphosphon
sirna
howev
direct
effect
fpp
chang
preosteoblast
miner
still
unclear
investig
requir
confirm
whether
downregul
fpp
via
sirna
influenc
osteoblastosteoclast
commun
colleagu
administ
sirna
silenc
prolyl
hydroxylas
domaincontain
protein
guanin
nucleotidebind
protein
alphastimul
activ
polypeptid
via
ambion
commerci
purchas
polyaminebas
transfect
agent
induc
enhanc
osteogenesi
vitro
bone
format
vivo
et
al
nevertheless
complex
differ
intercellular
mechan
regul
bone
format
remain
determin
prefabr
bone
defect
model
mechan
load
could
impair
clinic
applic
potenti
sirnabas
target
therapeut
jia
et
al
fabric
sirnasincorpor
chitosan
spong
within
two
type
sirnalipofectamin
complex
target
solubl
vascular
endotheli
growth
factor
receptor
casein
kinas
interact
protein
deliv
togeth
composit
sirnasdeliv
scaffold
show
satisfactori
angiogenesi
osteogenesi
bmsc
bone
repair
efficaci
vivo
jia
et
al
furthermor
guo
colleagu
also
report
similar
complex
demonstr
increas
osteogen
differenti
vitro
revers
bone
loss
osteoporot
mice
guo
et
al
zhang
colleagu
develop
boneform
surfacetarget
system
base
dioleoyl
trimethylammonium
propan
dotap
cation
liposom
display
high
affin
poorli
crystal
hydroxyapatit
ha
due
aspsers
moieti
osteogen
sirna
target
casein
interact
encompass
liposom
produc
significantli
increas
bone
microarchitectur
bone
format
healthi
osteoporot
rat
zhang
et
al
subsequ
liang
et
al
encapsul
sirna
effici
osteoblastspecif
aptamerfunction
lipid
nanoparticl
lnpssirna
promot
select
uptak
sirna
might
act
novel
desir
sirnabas
bone
anabol
strategi
improv
bone
mass
osteoporosi
liang
et
al
bonespecif
target
deliveri
system
discuss
promis
approach
special
deliv
sirna
drug
boneform
surfac
osteogen
cell
resid
thu
provid
potenti
solut
bottleneck
clinic
translat
sirnabas
bone
anabol
therapeut
near
futur
moreov
lipidoid
possess
similar
chemic
structur
liposom
anoth
new
type
lipidbas
nanoparticl
lipidoid
gain
significantli
higher
transfect
effici
lipofectamin
human
umbil
vein
endotheli
cell
huvec
low
serum
level
fulmer
ramasubramanian
et
al
perform
deliveri
dna
along
noggin
guanin
nucleotid
bind
protein
alphastimul
activ
polypeptid
gna
target
sirna
immort
human
foetal
osteoblast
cell
line
use
lipidoid
call
previous
report
effici
sirna
carrier
cho
et
al
studi
determin
osteoinduct
gene
deliveri
caus
decreas
cell
viabil
promot
cell
apoptosi
dosedepend
manner
emphas
signific
distinguish
biolog
effect
osteoinduct
signal
variou
cell
type
bone
regener
ramasubramanian
et
al
target
compon
triad
opgranklrank
sirna
techniqu
seem
promis
approach
regul
osteoclastogenesi
c
ordova
colleagu
report
local
administr
ranktarget
sirna
deliv
cation
liposom
dmapapdop
reveal
effect
imped
osteolysi
increas
bone
format
polyethylen
pe
particleinduc
osteolysi
model
mice
c
ordova
et
al
studi
demonstr
first
time
effect
inhibit
particleinduc
osteolysi
vivo
use
rankdirect
sirnasequ
interestingli
unexpect
bone
format
observ
sirnatr
mice
indic
inject
cation
liposom
might
produc
favour
local
anabol
microenviron
studi
remain
establish
understand
biolog
effect
deliveri
system
target
cell
tissu
may
use
improv
biocompat
sirna
deliveri
system
sirna
ddss
synthet
natur
polym
wide
studi
modifi
improv
intracellular
uptak
elabor
analys
previou
review
whitehead
langer
wang
colleagu
report
local
sirna
deliveri
strategi
target
select
suppress
osteoclastogenesi
bone
site
osteoporosi
fabric
passiv
phagocytetarget
poli
lacticcoglycol
acid
plga
microparticl
incorpor
within
biomed
grade
calciumbas
inject
bone
cement
deliv
rank
sirna
osteoclast
precursor
provid
proof
concept
use
local
deliv
sirna
therapeut
strategi
direct
target
osteoporosi
site
wang
et
al
discuss
role
glucocorticoid
gc
osteoblastogenesi
osteoclastogenesi
review
therefor
design
sirna
target
gc
receptor
gcr
could
feasibl
approach
regul
function
hbmsc
explor
vitro
studi
wei
et
al
moreov
hong
et
al
report
gcrsirnadeliv
plga
microparticl
show
effect
inhibit
detriment
effect
endogen
gc
hbmsc
improv
osteogen
prolifer
differenti
hong
et
al
wang
et
al
fabric
sitespecif
bonetarget
system
base
octaaspart
acid
sequenc
bisphosphon
demonstr
favor
recogn
strongli
bind
biominer
eg
hydroxyapatit
surfac
studi
highli
hydrophil
synthet
polym
n
methacrylamid
hpma
coupl
alendron
bisphosphon
deliv
semaphorin
sirna
specif
bone
site
exhibit
partial
counteract
bone
loss
origin
osteoporosi
recent
research
team
fabric
plla
scaffold
incorpor
improv
bone
format
osteoporosisrel
bone
defect
also
known
prove
express
osteoclast
neg
regul
osteoblastogenesi
negishi
koga
et
al
report
physic
chemistri
boneform
surfac
cover
osteoblast
character
lowli
crystal
hydroxyapatit
physic
chemistri
boneresorpt
surfac
cover
osteoclast
character
highli
crystal
hydroxyapatit
wang
et
al
two
bonetarget
molecul
aspsers
asp
demonstr
effect
bone
target
function
zhang
et
al
wang
et
al
stronger
affin
aspsers
lowli
crystal
hydroxyapatit
rather
highli
crystal
hydroxyapatit
provid
explan
preferenti
bind
aspsers
boneform
surfac
wherea
stronger
affin
asp
highli
crystal
hydroxyapatit
rather
lowli
crystal
hydroxyapatit
produc
preferenti
bind
asp
boneresorpt
surfac
zhang
et
al
differ
affin
two
molecul
boneform
resorpt
surfac
deserv
great
attent
sirnabas
bone
anabol
therapi
except
polymerbas
particl
polymer
hydrogel
control
three
dimension
network
also
use
sirna
deliveri
bone
regener
nguyen
colleagu
describ
local
sustain
noggin
sirna
dd
base
engin
poli
ethylen
glycol
peg
hydrogel
scaffold
exhibit
control
releas
cours
week
wellguid
osteogen
differenti
hbmsc
nquyen
et
al
work
provid
effici
methodolog
realiz
control
stem
cell
fate
bone
tissu
engin
futur
furthermor
manaka
colleagu
examin
efficaci
nogginsirna
deliv
biodegrad
hydrogel
polyd
llactic
acidpdioxanonepolyethylen
glycol
block
copolym
pladxpeg
display
enhanc
bmpinduc
ectop
bone
format
manaka
et
al
noggin
major
extracellular
antagonist
bmp
noggin
silenc
sirna
exhibit
significantli
acceler
osteoblast
differenti
vitro
promot
new
bone
format
vivo
wan
et
al
takyama
et
al
howev
effect
local
inhibit
noggin
express
target
sirna
transfect
vivo
dramat
expect
vitro
find
may
due
inadequ
dose
noggintarget
sirna
andor
insuffici
efficaci
deliveri
system
sirna
cell
even
though
plenti
sirnabas
target
system
effect
confirm
vitro
mention
number
vivo
investig
badli
requir
determin
applic
efficaci
sirnabas
target
therapeut
bone
disord
addit
investig
potent
applic
sirna
combat
bone
defect
resorpt
sirna
could
also
effici
anticip
tool
restrain
tumour
develop
metastasi
skelet
system
sequencespecif
gene
silenc
tool
posttranscript
level
sirna
wide
explor
target
specif
oncogen
lead
effect
imped
bone
tumour
growth
amelior
chemosensit
wide
acknowledg
vegf
regul
tumour
angiogenesi
directli
increas
neovascular
vascular
permeabl
remodel
bradshaw
et
al
silenc
vegf
via
sirna
confirm
suppress
osteosarcoma
angiogenesi
promot
tumour
cell
apoptosi
via
activ
phosphoinositid
protein
kinas
b
akt
signal
pathway
cell
peng
et
al
moreov
combin
applic
vegfsirna
neoadjuv
chemotherapi
manifest
prefer
synergist
therapeut
effect
simpl
biolog
therapi
vegfsirna
plu
antiangiogenesi
chemotherapi
osbear
rat
suggest
addit
neoadjuv
chemotherapi
might
benefici
enhanc
therapeut
effici
vegfsirna
zhu
mei
translat
control
tumour
protein
tctp
known
famili
member
describ
stabil
promot
antiapoptot
activ
sever
oncogen
thu
facilit
progress
tumour
cell
liu
et
al
sirnamedi
silenc
tctp
display
obvious
promot
apoptosi
cell
line
togeth
inhibit
develop
xenograft
nude
mice
shen
et
al
cell
adhes
molecul
belong
immunoglobulin
superfamili
identifi
critic
mediat
tumour
progress
base
discoveri
high
express
androgeninsensit
metastat
prostat
cancer
pc
cell
line
sung
et
al
investig
therapeut
effect
liposomeencapsul
exhibit
admir
suppress
pc
prolifer
bone
metastasi
inhibit
matrix
activ
nfkb
pathway
sung
et
al
howev
mechan
regul
mesenchymaltoepitheli
transit
emt
relat
gene
express
confer
enhanc
motil
metastat
capabl
pc
remain
determin
multidrug
resist
mdr
repres
enorm
barrier
treatment
osteosarcoma
recoveri
rate
dramat
decreas
patient
recurr
caus
mdr
schwartz
et
al
overexpress
membranebound
drug
transport
protein
includ
mdrrelat
protein
pglycoprotein
pag
breast
cancer
resist
protein
bcrp
one
consid
caus
mdr
lourda
et
al
overcom
mdr
treat
os
susa
colleagu
fabric
lipidmodifi
dextranbas
polymer
nanoparticl
suggest
approach
could
revers
drug
resist
mdr
cell
line
via
effect
suppress
pag
express
susa
et
al
similarli
sirnamedi
downregul
pag
also
display
restor
chemosensit
chemoresist
carcinoma
sarcoma
cell
line
perez
et
al
improv
therapeut
effici
mdr
chen
colleagu
studi
multifunct
nanoparticl
modifi
deliveri
properti
chen
et
al
work
liposomepolycationdna
lpd
sequenti
modifi
cation
lipid
vegfsirna
doxorubicin
dox
improv
drug
uptak
penetr
suppress
angiogenesi
sake
inhibit
drug
efflux
mediat
pglycoprotein
final
design
anion
lpd
exhibit
significantli
improv
entrap
effici
dox
cation
lpd
explor
first
codeliv
chemotherapi
agent
oncogenetarget
sirna
overcom
mdr
differ
carrier
provid
novel
insight
design
multifunct
genedeliveri
system
solv
mdr
futur
clinic
practic
furthermor
sirnabas
gene
deliveri
system
also
appli
bone
neoplasm
cheng
et
al
observ
express
affect
recurr
rate
gctb
clinicopatholog
analysi
case
knockdown
sirna
reveal
dramat
inhibit
prolifer
migrat
invas
gctb
cell
vitro
cheng
et
al
lau
colleagu
found
import
factor
facilit
gct
tumourigenesi
via
suppress
bind
knockdown
sirna
manifest
greatli
decreas
prolifer
promot
apopotsi
gct
stromal
cell
lau
et
al
bertrand
colleagu
describ
silenc
one
critic
oncogen
ewe
sarcoma
sirna
deliv
hydrogen
cation
nanodiamond
ndh
enhanc
cytotox
impact
vincristin
ewe
sarcoma
es
cell
bertrand
et
al
nanodiamond
nd
suitabl
surfac
modif
therapi
target
label
moieti
due
carbonrel
surfac
chemistri
report
deliv
sirna
es
cell
target
oncogen
alhaddad
et
al
sirna
deliveri
system
exhibit
strongli
suppress
oncogen
express
also
enhanc
cytotox
effect
vincristin
chemiotherapeut
agent
alreadi
use
clinic
treat
ewe
sarcoma
therefor
ndh
constitut
great
promis
platform
sirna
deliveri
antibon
cancer
therapi
cancerinduc
bone
pain
sever
clinic
issu
affect
qualiti
life
patient
even
therapeut
outcom
recent
sirnabas
gene
treatment
emerg
anticip
method
attenu
bone
cancer
pain
bcp
huang
colleagu
report
silenc
phosphatidylinositol
cb
allevi
bcp
increas
glial
excit
huang
zhang
tolllik
receptor
preliminarili
corrobor
import
synergist
factor
involv
proinflammatori
cytokinemedi
neurontogli
signal
activ
lan
et
al
sirnamedi
downregul
yield
obvious
attenu
nocicept
rat
bcp
pan
et
al
report
hyperact
plateletderiv
growth
factor
pdgf
could
induc
tactil
allodynia
select
inhibit
pdgf
receptor
pdgfr
produc
suppress
tactil
allodynia
thermal
hyperalgesia
masuda
et
al
base
discoveri
xu
colleagu
observ
sirnamedi
pdgf
knockdown
effect
reliev
bcp
block
akterk
signal
pathway
xu
et
al
central
sensit
promot
develop
bcp
camp
respons
element
bind
protein
creb
posit
regul
crebregul
transcript
turn
play
critic
role
central
sensit
bourtchuladz
et
al
liang
colleagu
observ
suppress
spinal
sirna
result
effect
reduc
bcp
mice
orthotop
implant
os
cell
liang
et
al
studi
discuss
may
provid
insight
mechan
cancer
pain
contribut
develop
therapeut
strategi
clinic
treatment
bone
cancer
pain
nonleth
diseas
osteoarthr
osteonecrosi
heterotop
ossif
also
exert
mani
advers
effect
qualiti
life
patient
recent
sirnabas
target
gene
technolog
offer
potenti
benefit
treatment
bonerel
diseas
corticosteroid
wide
use
infecti
rheumatoid
diseas
sever
acut
respiratori
syndrom
sar
rheumatoid
arthriti
howev
steroidassoci
osteonecrosi
saon
usual
occur
puls
steroid
applic
diseas
xie
et
al
destruct
bone
repair
one
import
patholog
chang
involv
saon
character
obviou
bone
resorpt
vascular
hyperperm
vegf
mainli
contribut
vascular
hyperperm
potenti
mediat
osteoclast
bone
resorpt
kim
et
al
src
downstream
molecul
vegf
signal
encod
csrc
gene
particip
osteoclast
bone
resorpt
vegfinduc
vascular
permeabl
boyc
et
al
zheng
colleagu
perform
systemat
evalu
therapeut
effici
src
blockag
sirna
regard
saon
vitro
vivo
reveal
sirnamedi
src
suppress
significantli
suppress
vegfinduc
osteoclast
bone
resorpt
vascular
hyperperm
destroy
osteoclast
cytoskeleton
maintain
endotheli
junction
integr
zheng
et
al
cao
et
al
moreov
determin
upregul
vegf
express
chondrocyt
deriv
femor
head
osteonecrosi
pig
mediat
partial
silenc
sirna
transfect
led
obvious
decreas
vegf
express
zhang
et
al
therefor
suppress
vegf
express
use
sirna
technolog
might
gain
desir
therapeut
valu
prevent
destruct
bone
repair
due
saon
li
colleagu
report
blockag
peroxisom
proliferatoractiv
receptorg
pparg
sirna
inhibit
adipogenesi
enhanc
osteogenesi
bmsc
thu
provid
novel
avenu
imped
develop
saon
pparg
specif
transcript
factor
correl
adipogenesi
knockout
pparg
bmsc
led
increas
osteoblastogenesi
cao
et
al
evid
indic
pparg
signific
target
gene
develop
saon
analog
mirnamedi
target
therapi
oa
sirnabas
genespecif
therapeut
display
potenti
treatment
valu
degen
diseas
well
report
facilit
progress
oa
due
preferenti
digest
type
ii
collagen
earli
stage
cartilag
degrad
takaishi
et
al
akagi
colleagu
demonstr
intraarticular
inject
sirna
earli
stage
surgicallyinduc
murin
oa
model
show
delay
cartilag
degrad
akagi
et
al
howev
remain
determin
whether
durat
sirna
retent
alter
joint
experiment
oa
knockdown
effect
mediat
sirna
tissu
cartilag
also
investig
autolog
chondrocyt
implant
aci
cellbas
therapi
first
report
brittberg
et
al
sinc
wide
perform
patient
oa
howev
success
aci
alway
depend
phenotyp
stabil
chondrocyt
legendr
et
al
observ
gene
blockag
collagen
type
alpha
high
temperatur
requir
factor
via
sirna
induc
distinctli
enhanc
differenti
index
chondrocyt
cultur
hypox
condit
thu
offer
potenti
opportun
explor
novel
acibas
treatment
futur
legendr
et
al
ollitrault
et
al
corrobor
overexpress
mediat
induc
aggrav
degrad
cartilag
matrix
oa
significantli
inhibit
express
level
ji
et
al
sirnamedi
blockag
demonstr
protect
effect
cartilag
degrad
chu
et
al
moreov
intraarticular
deliveri
hypoxiainduc
sirna
chondrocytehom
nanoparticl
result
consider
decreas
express
catabol
protein
involv
progress
oa
vegf
thu
provid
better
prevent
cartilag
degener
oa
patient
pi
et
al
hypoxia
signal
pathway
involv
bone
cartilag
regener
comprehens
summar
detail
review
stier
et
al
research
badli
need
determin
hypoxiaassoci
gene
target
strategi
improv
therapeut
potenti
regard
oa
addit
sirna
also
use
explor
potenti
therapi
autosom
domin
diseas
bone
character
sever
morbid
lack
effect
treatment
verifi
onberg
diseas
also
call
autosom
domin
osteopetrosi
type
character
significantli
inhibit
osteoclast
activ
mainli
due
heterozyg
missens
mutat
gene
capulli
et
al
report
sirnabas
explor
use
cation
polym
transfect
reagent
vitro
vivo
lead
overal
improv
osteopetrot
bone
phenotyp
capulli
et
al
studi
provid
feasibl
sirnabas
therapeut
strategi
emphas
translat
impact
futur
treatment
therapeut
neglect
osteopetrosi
primari
role
deliveri
system
facilit
cellular
uptak
mirna
sirna
target
site
deliveri
system
also
protect
nucleic
acid
prematur
nucleas
degrad
affect
specif
function
rna
molecul
well
document
mirna
sirna
prone
nucleas
degrad
low
cell
membran
penetr
capabl
due
highli
charg
backbon
addit
inflammationrel
cell
toxic
unintend
gene
knockdown
caus
offtarget
effect
deriv
applic
mirna
sirna
paid
great
attent
deliv
vivo
thu
establish
ration
effect
mirnasor
sirnasbas
drug
deliveri
system
ddss
great
import
target
therapeut
bone
disord
sinc
mirna
sirna
similar
physicochem
properti
doublestrand
rna
nucleotid
intracellular
site
action
requir
enzymat
function
risc
activ
target
mrna
similar
deliveri
technolog
appli
type
rna
molecul
mainli
two
type
ddss
transfer
mirna
sirna
viralmedi
nonvir
vector
virus
lentivirus
retrovirus
adenovirus
herpesvirus
appear
first
choic
mirna
sirna
deliveri
extrem
effici
transfer
rnaencod
vector
nuclei
mammalian
cell
ensur
high
express
rna
almost
gene
therapi
clinic
trial
involv
applic
viral
vector
deliv
nucleic
acid
due
high
transduct
effici
addit
longterm
express
achiev
use
virus
howev
major
limit
viral
vector
biolog
safeti
issu
includ
possibl
carcinogen
high
viral
toxic
verifi
immunogen
wang
et
al
therefor
despit
inferior
transfect
effici
viral
vector
nonvir
transfer
system
low
acut
toxic
lower
product
cost
noninfect
nonimmunogen
emerg
desir
approach
deliv
mirna
sirna
vivo
castanotto
et
al
two
major
categori
nonvir
ddss
use
mirna
sirna
deliveri
therapeut
applic
lipidbas
polymerbas
system
apart
advantag
mention
ie
rel
favour
safeti
profil
low
product
cost
nonvir
vector
highli
versatil
easili
modifi
promot
deliveri
effici
exampl
improv
serum
stabil
extend
circul
time
pegyl
buyen
et
al
achiev
sitespecif
deliveri
incorpor
target
ligand
ie
aspsers
asp
zhang
et
al
liang
et
al
despit
effort
develop
suitabl
mirna
sirna
deliveri
system
clinic
applic
poor
correl
vitro
vivo
efficaci
also
observ
often
report
deliveri
system
function
effect
vitro
fail
vivo
poor
pharmacokinet
profil
toxic
issu
immun
respons
nonspecif
uptak
lv
et
al
therefor
success
therapeut
mirna
sirna
highli
depend
avail
effici
safe
deliveri
system
select
exampl
viral
nonvir
deliveri
system
explor
deliv
therapeut
mirna
sirna
vivo
vitro
summar
tabl
tabl
respect
better
understand
nucleic
acid
gene
deliveri
pleas
refer
chapter
summar
akita
et
al
first
clinic
trial
mirna
therapi
began
second
one
start
earli
contrast
first
clinic
trial
sirna
therapeut
initi
ozcan
et
al
search
clinicaltrialsgov
date
found
approxim
sirna
candid
reach
variou
stage
clinic
trial
treatment
differ
diseas
approxim
trial
focus
tumourrel
target
therapeut
howev
clinic
develop
mirna
therapeut
lag
significantli
two
mirna
therapeut
mention
indic
treatment
cancer
rel
slow
progress
mirna
therapeut
mainli
due
uncertain
mechan
complex
role
action
specif
earli
year
discoveri
addit
divers
potenti
applic
eg
drug
target
biomark
mirna
extens
discuss
might
also
detract
develop
therapeut
agent
howev
therapeut
mirna
sirna
clinic
trial
either
topic
administr
ie
ocular
dermal
system
target
liver
inject
rna
end
nonspecif
anyway
unfortun
clinic
trial
initi
bonerel
disord
time
write
therefor
mani
effort
still
must
exert
improv
better
understand
mirna
sirna
therapeut
discuss
latter
synthet
mirna
sirna
hold
great
promis
new
class
therapeut
agent
silenc
gene
interest
studi
treatment
variou
human
diseas
cancer
genet
disord
cardiovascular
diseas
bonerel
disord
well
document
mirna
sirna
similar
physicochem
properti
involv
regul
gene
silenc
yet
mechan
action
differ
thu
requir
sequenc
design
therapeut
applic
distinct
major
differ
former
multipl
mrna
target
wherea
latter
highli
specif
one
target
therefor
complex
multigen
diseas
mirna
might
predomin
sirna
design
mirna
straightforward
sirna
use
bone
therapeut
sequenc
former
almost
entir
ident
endogen
mirna
interest
moreov
mirna
advantag
sirna
therapeut
complex
multigen
bonerel
diseas
congenit
disloc
hip
cdh
rachischisi
requir
modul
multipl
pathway
effect
treatment
abil
inhibit
express
number
target
gene
often
work
togeth
network
within
cellular
pathway
whole
diseas
lentiviru
vector
sd
rat
intraarticular
inject
protect
effect
cartilag
degrad
chu
et
al
chondrocytehom
nanoparticl
mous
intraarticular
inject
inhibit
catabol
protein
express
oa
maintain
cartilag
integr
pi
et
al
lipofectamin
human
osteoclast
mice
subcutan
inject
inhibit
increas
bone
mass
grow
mice
capulli
et
al
phenotyp
potenti
alter
singl
mirna
sequenc
contrast
therapeut
potenti
sirna
sometim
limit
abil
target
one
specif
gene
therefor
could
challeng
employ
sirna
regul
complex
bonerel
diseas
base
overal
analysi
mirnaand
sirnabas
therapeut
mention
know
therapi
emerg
excel
genet
tool
bone
biolog
hold
great
therapeut
promis
field
gene
therapi
howev
sever
univers
challeng
face
applic
mirna
sirna
therapeut
although
one
distinct
featur
differenti
sirna
mirna
sirna
design
silenc
express
specif
target
mrna
lead
downregul
unintend
unpredict
target
also
call
offtarget
effect
three
main
offtarget
effect
sirna
discov
potenti
unwant
side
effect
almost
decad
ago
jackson
linsley
firstli
silenc
mani
unintend
gene
partial
sequenc
complementar
alway
produc
advers
effect
normal
biolog
addit
inflammatori
respons
caus
either
sirna
dd
use
final
satur
endogen
rnai
machineri
could
inevit
affect
normal
mirna
function
thu
one
major
challeng
sirna
therapi
reduc
offtarget
effect
verifi
compromis
therapeut
effect
specif
even
lead
cell
death
fedorov
et
al
also
import
clear
overview
barrier
vivo
treatment
mirna
sirna
obstacl
mirna
sirna
deliveri
depend
target
organ
rout
administr
differ
vivo
administr
rout
encount
differ
physiolog
barrier
instanc
intraven
administr
commonli
use
techniqu
endotheli
wall
vasculatur
serv
primari
barrier
rna
deliveri
moreov
mononuclear
phagocyt
reticuloendotheli
system
respons
physiolog
barrier
hinder
mirna
sirna
reach
target
lead
reduc
therapeut
efficaci
furthermor
mirna
sirna
therapeut
face
major
challeng
prolong
stabl
deliveri
improv
potenc
minim
cell
tissu
toxic
final
sever
current
vitro
studi
therapeut
rnai
provid
result
larg
compar
vivo
result
reagent
disconnect
current
barrier
predict
reliabl
clinic
translat
mirna
sirna
exert
gene
silenc
effect
physiolog
patholog
process
posttranscript
level
target
relev
specif
mrna
repres
innov
promis
breakthrough
field
genet
engin
remark
progress
made
biolog
diagnost
therapeut
potenti
two
small
noncod
rna
bone
metabol
bonerel
disord
experi
antisens
gene
therapi
contribut
rapid
progress
mirna
sirna
clinic
studi
particular
technolog
chemic
modif
deliveri
nucleic
acid
develop
previous
appli
mirna
sirna
thorough
investig
full
understand
function
mirna
involv
variou
bonerel
physiolog
patholog
activ
hold
great
signific
design
specif
accur
genesilenc
therapeut
mediat
via
sirna
current
sirna
demonstr
obviou
superior
mirna
progress
advanc
clinic
trial
discuss
orthopaed
applic
therapeut
rna
advantag
surgeon
enter
site
therapi
surgic
repair
allow
rna
administ
local
site
topic
combin
devic
attract
aspect
mirna
sirna
therapeut
abil
target
virtual
gene
might
possibl
proteinbas
drug
small
molecul
therapeut
efficaci
mirna
sirna
success
shown
vitro
vivo
sever
technic
barrier
still
must
overcom
rna
molecul
use
clinic
major
literatur
focus
mirna
sirna
express
gene
target
need
assess
process
architectur
close
relat
target
effect
msc
differenti
remain
need
studi
evalu
regul
mirna
sirna
process
biogenesi
osteogenesi
relat
protein
could
lead
novel
mechan
mirnaor
sirnabas
intervent
bone
disord
avoid
silenc
unintend
gene
lower
concentr
mirna
sirna
use
could
effect
approach
reduc
unwant
sideeffect
mention
decreas
concentr
minim
effect
limit
also
significantli
allevi
burden
rnai
machineri
avoid
disrupt
physiolog
process
proper
therapeut
use
sequenc
rna
must
care
design
avoid
specif
nonspecif
unwant
side
effect
immun
respons
avoid
offtarget
effect
induc
sirna
one
feasibl
approach
reduc
complementar
seed
region
nucleotid
end
sirna
utr
mrna
addit
sirna
low
thermodynam
stabil
duplex
seed
region
guid
strand
sirna
target
mrna
sinc
low
seedtarget
duplex
stabil
reduc
abil
sirna
trigger
seeddepend
offtarget
effect
naito
uitei
use
nonvir
vector
includ
polymerbas
lipidbas
deliveri
system
offer
advantag
better
safeti
profil
lower
product
cost
compar
viral
vector
despit
inferior
deliveri
effici
addit
also
addit
design
criteria
promot
efficaci
mirna
sirna
therapeut
bone
incorpor
mirnaor
sirnaload
particl
insid
inject
biodegrad
matric
might
highli
favor
local
deliveri
mirna
sirna
site
bone
defect
osteoporosi
tumour
thu
maxim
therapeut
effect
meanwhil
approach
would
also
circumv
mani
physiolog
barrier
case
system
administr
addit
target
moieti
consid
anoth
signific
approach
improv
efficaci
sirna
deliveri
three
commonli
use
moieti
bonerel
disord
bisphosphon
bonespecif
oligopeptid
aptam
discuss
zhang
et
al
liang
et
al
wang
et
al
zhang
et
al
zhang
et
al
discoveri
molecul
high
affin
bone
surfac
improv
therapeut
effect
clinic
relev
mirnaor
sirnabas
deliveri
system
addit
improv
therapeut
effect
mirna
sirna
therapi
analys
also
safeti
issu
consid
move
technolog
clinic
set
import
fabric
dd
inject
matric
biocompat
degrad
biomateri
degrad
byproduct
noncytotox
materi
clear
rapidli
readili
bodi
without
accumul
liver
organ
cation
polym
extens
use
oligonucleotid
deliveri
due
capabl
complex
readili
rna
dna
mention
wang
et
al
zhang
et
al
c
ordova
et
al
howev
upon
degrad
cation
polym
induc
cytotox
effect
surround
cell
caus
red
blood
cell
lysi
fischer
et
al
therefor
hydrolys
polym
cyclodextrincontain
polym
degrad
readili
rapidli
could
gain
greater
attent
design
dd
involv
mirnaor
sirnabas
therapeut
addit
durat
silenc
effect
singl
dose
mirna
sirna
depend
sever
factor
stabil
rna
molecul
rate
rna
releas
deliveri
system
type
target
tissu
togeth
halflif
turnov
rate
target
protein
good
understand
area
could
also
contribut
ration
design
therapeut
strategi
promot
clinic
outcom
mirna
sirna
treatment
instanc
pegyl
nanoparticl
incorpor
target
ligand
might
effect
avoid
reticuloendotheli
system
re
clearanc
thu
prolong
circul
time
stabil
mirna
sirna
deliveri
system
improv
stabil
mirna
sirna
therapeut
agent
relev
chemic
modif
rna
develop
initi
address
issu
success
chemic
modif
compromis
genesilenc
effici
rna
molecul
major
type
chemic
modif
commonli
investig
mirna
sirna
design
includ
lock
unlock
nucleic
acid
ribos
oh
group
phosphorothio
modif
allerson
et
al
differ
rna
modif
use
serv
variou
function
proper
chemic
modif
also
effect
approach
reduc
offtarget
effect
analys
effici
gene
silenc
also
achiev
nake
rna
howev
approach
might
limit
local
administr
organ
lung
eye
addit
proper
chemic
modif
incorpor
specif
nucleas
inhibitor
rna
molecul
could
benefici
improv
stabil
nucleas
activ
airway
fluid
lung
vitreou
humour
eye
although
mirnaand
sirnabas
therapi
remain
nascent
field
bone
expect
advanc
rna
design
specif
biochem
modif
better
understand
effect
durat
gene
silenc
mirna
sirna
realiz
gradual
progress
translat
preclin
experi
clinic
trial
near
futur
author
report
conflict
interest
work
